Introduction Ubamatamab (REGN4018; mucin16 [MUC16] x CD3 bispecific antibody) promotes T-cell-mediated killing of ovarian cancer (OC) cells in preclinical studies. This activity is enhanced by the anti-PD-1 antibody cemiplimab. We present first-in-human ubamatamab +/- cemiplimab dose escalation results in recurrent OC.
Methods Patients with recurrent platinum-experienced OC received weekly intravenous ubamatamab 0.3–800 mg after step-up dosing. Patients in combination cohorts received intravenous cemiplimab 350 mg every 3 weeks beginning Day 29–36. Endpoints assessed safety (primary), clinical activity (secondary), and correlatives of tumor MUC16 immunohistochemistry and serum CA125 (exploratory).
Results 109 patients (N=74 monotherapy/N=35 combination) were enrolled. Median number of prior therapies was 5 (range 1–17). Commonest treatment-related adverse events of any grade occurred in the first 4 weeks of treatment, including pain (75.2%; Grade 1–2 56.9%; Grade 3 18.3%) and cytokine release syndrome (72.5%; all Grade 1–2) (table 1), with few of these events after addition of cemiplimab. In efficacy analyses (n=42 monotherapy/n=22 combination), ORR was 14.3%/18.2%, median duration of response was 13.7/8.3 months, and CA125 response (GCIG criteria) was 31.0%/22.7%. All patient tumors expressed MUC16 by immunohistochemistry. Responses with ubamatamab monotherapy were observed across a range of MUC16 expression levels. Response rates and PFS increased with increasing number and intensity of MUC16+ cells. CA125 response was associated with improved PFS (monotherapy: hazard ratio 0.35; 95% CI 0.17–0.72).
Conclusion/Implications Ubamatamab +/- cemiplimab demonstrated acceptable safety and evidence of clinical activity in heavily pretreated OC. An ongoing randomised Phase 2 study is evaluating ubamatamab alone and with cemiplimab.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.